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Background: Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical
practice is difficult. Here, we evaluate adherence to anastrozole in the International Breast Cancer Intervention Study (IBIS)-II
prevention and ductal carcinoma in situ (DCIS) trials, and its association with early symptoms.
Patients and methods: In the prevention trial, 3864 postmenopausal women were randomized to placebo versus
anastrozole. A total of 2980 postmenopausal women with DCIS were randomized to tamoxifen versus anastrozole. Adherence
to trial medication was calculated using the Kaplan–Meier method and all P-values were two-sided.
Results: In the prevention trial, adherence was 65.8% [anastrozole (65.7%) versus placebo (65.9%); HR¼ 0.97 (0.87–1.09),
P¼ 0.6]. Adherence was lower for those reporting arthralgia in the placebo group (P¼ 0.02) or gynecological symptoms in the
anastrozole group (P¼ 0.003), compared with those not reporting these symptoms at 6months. In the DCIS study, adherence
was 66.7% [anastrozole (67.5%) versus tamoxifen (65.8%); HR¼ 1.06 (0.94–1.20), P¼ 0.4]. Hot flashes were associated with
greater adherence in the anastrozole arm (P¼ 0.02). In both studies, symptoms were mostly mild or moderately severe, and
adherence decreased with increasing severity for most symptoms. Drop-outs were highest in the first 1.5 years of therapy in
both trials.
Conclusions: In the IBIS-II prevention and DCIS trials, over two-thirds of women were adherent to therapy, with no differences
by treatment groups. Participants who reported specific symptoms in the IBIS-II prevention trial had a small but significant effect
on adherence, which strengthened as severity increased. Strategies to promote adherence should target the first year of
preventive therapy.
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Introduction
Breast cancer is the most frequent cancer among women world-
wide, with an estimated 1.67 million new cancer cases diagnosed
in 2012 [1] and hence the prevention of breast cancer is a recog-
nized priority [2]. There have been increases in female breast can-
cer incidence rates since the 1970s, although rates appear to be
stabilizing among younger women and in more economically
developed countries [3, 4].
Preventive therapy for women at high risk of developing breast
cancer or those with a diagnosis of ductal carcinoma in situ
(DCIS) can reduce disease burden. Aromatase inhibitors (AIs)
reduce breast cancer risk among high-risk postmenopausal
women. Data from the International Breast Cancer Intervention
Study II (IBIS-II) prevention trial show that women randomly
assigned to receive anastrozole (1 mg/day) were over 50% less
likely to be diagnosed with breast cancer compared with those
taking a matching placebo [5]. A 65% relative risk reduction of
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invasive breast cancer was shown among women taking exemes-
tane compared with placebo in the MAP.3 trial [6].
Two major AI prevention trials have been done among women
with DCIS. In the IBIS-II DCIS trial, anastrozole was non-inferior
to tamoxifen in reducing breast cancer recurrence [7]. The
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-
35 trial showed statistically significant improvements in breast
cancer-free interval among women taking anastrozole compared
with tamoxifen [8]. Implementing preventive therapy in routine
clinical practice for high-risk women is difficult due to reluctance
among clinicians to prescribe the medication [9], low patient
uptake [10–12], and sub-optimal adherence to therapy [10, 12,
13]. A major factor affecting implementation is side-effects [14,
15]. Patients are less willing to initiate preventive therapy if they
perceive it to be linked with side-effects [16]. In the IBIS-I preven-
tion trial, rates of adherence were lower among women reporting
side-effects, but this finding was consistent in both tamoxifen and
placebo groups [13]. Little is known about the acceptance of anas-
trozole in women at high risk of developing breast cancer.
Data from the IBIS-II prevention trial indicate women taking
anastrozole are more likely to experience musculoskeletal events,
vasomotor symptoms, and hypertension compared with those
taking placebo [5]. In the IBIS-II DCIS trial, women taking anas-
trozole were more likely to experience fractures, musculoskeletal
events, hypercholesterolemia, and strokes compared with women
taking tamoxifen [7]. Large proportions of women reported
arthralgia and hot flashes with both placebo [5] and tamoxifen
[7], indicating that anastrozole may not be solely responsible for
these patient reported side-effects. Here, we assess the association
between participant-reported symptoms on adherence to anas-
trozole in the IBIS-II prevention and DCIS trials.
Methods
Participants
The IBIS-II prevention study is an international, randomized, double-
blind, and placebo-controlled trial conducted in 18 countries [5].
Postmenopausal women (n¼ 3864) aged 40–70 years were randomly
assigned to either 1 mg anastrozole or matching placebo daily for 5 years.
The trial is registered, number ISRCTN31488319. The IBIS-II DCIS
study recruited 2980 postmenopausal women with locally excised estro-
gen receptor positive or progesterone positive DCIS. Women were
randomized to receive 1 mg/day oral anastrozole or 20 mg/day oral
tamoxifen for 5 years [7]. The trial is registered, number
ISRCTN37546358. Details of patient cohorts and characteristics are pro-
vided in supplementary material, available at Annals of Oncology online.
Adherence
Adherence was defined as the period between trial randomization date
and the date of the final follow-up visit [17]. Adherence (full/deviation/
holiday/stopped) and further details on non-adherence were recorded on
each follow-up CRF at 6-monthly visits. Pre-defined rules for assessing
adherence were developed and used by SS to review all CRFs (supplemen
tary material, available at Annals of Oncology online). Women who self-
reported medication cessation at a visit were classified as non-adherent.
Each woman was assessed for persistent use of medication for at least
4.5 years (adherent) or stopping before 4.5 years (non-adherent).
All women in the prevention and DCIS IBIS-II trials have finished 5 years
of active treatment.
Participant symptoms
Symptoms were assessed at each follow-up visit using pre-defined items
for arthralgia (arthritis, arthrosis, or joint disorder), hot flashes/night
sweats, vaginal discharge, irregular vaginal bleeding, eye diseases/cata-
racts, and osteoporosis/fractures. Vaginal discharge and irregular vaginal
bleeding were grouped together as gynecological symptoms because they
are similar. All symptoms were classified as mild, moderate, or severe as
judged by the women. The most severe gynecological symptom was used
when computing this item.
Statistical analysis
Adherence to trial medication was calculated using the Kaplan–Meier
method [18], both overall and by treatment group separately. Further
details of statistical methods are provided in supplementary material,
available at Annals of Oncology online.
Results
IBIS-II prevention study
Postmenopausal women (n¼ 3864) were randomized to receive
1 mg/day anastrozole versus matching placebo. Women were
excluded from the current analysis if they did not start their allo-
cated medication (n¼ 77) or if they were ineligible (n¼ 24) (sup
plementary Figure S1, available at Annals of Oncology online).
Hence, 3763 women (97.4%) were included in this analysis (1868
anastrozole versus 1895 placebo). For the analyses investigating
associations between early reported symptoms and adherence,
those who did not reach the 6 month visit were excluded
(n¼ 159). Baseline participant characteristics were balanced
between treatment groups (supplementary Table S1, available at
Annals of Oncology online).
Overall, 1287 women (34.2%) were non-adherent. For women
randomized to anastrozole, adherence was non-significantly
lower compared with those on placebo [HR¼ 0.97 (0.87–1.09),
P¼ 0.6] (Figure 1). Mean time on the treatment was similar in
both treatment arms (anastrozole 3.90 years versus placebo
4.00 years). Overall, annual drop-out rates were highest within
the first 12–18 months of follow-up (Figure 1) and declined
sharply thereafter. The following predictors were significantly
associated with adherence in the univariate model: 60 years or
older, hysterectomy, oophorectomy, natural menopause, and
previous participation in the IBIS-I prevention trial (supplemen
tary Table S2, available at Annals of Oncology online). When
adherence was investigated adjusted for all previous significant
predictors, being older than 60 years of age [OR¼ 1.17 (1.01–
1.34), P¼ 0.03], not having had a hysterectomy [OR¼ 0.75
(0.59–0.96), P¼ 0.03], and previous participation in the IBIS-I
trial [OR¼ 1.38 (1.14–1.67), P¼ 0.001] remained significant
predictors for adherence.
At 6 months of follow-up (n¼ 3604), significantly more
women randomized to anastrozole compared with placebo
reported arthralgia (31.5% versus 25.5%, P< 0.001), hot flashes/
night sweats (42.6% versus 34.1%, P< 0.001), and gynecological
symptoms (11.4% versus 9.0%, P¼ 0.02). Women reporting
arthralgia [HR¼ 0.85 (0.75–0.97), P¼ 0.01] or gynecological
symptoms [HR¼ 0.78 (0.65–0.94), P¼ 0.008] were significantly
less likely to be adherent at 4.5 years than those not reporting
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these symptoms (Table 1). However, absolute differences in
adherence were small.
For women reporting arthralgia at 6 months, only those
randomized to placebo were significantly less adherent
[HR¼ 0.81 (0.67–0.97), P¼ 0.02]. There was no significant dif-
ference in non-adherence for those randomized to anastrozole
[HR¼ 0.90 (0.75–1.07), P¼ 0.2] (Figure 2). Women randomized
to anastrozole and reporting gynecological symptoms were 31%
less likely to be adherent at 4.5 years [HR¼ 0.69 (0.55–0.88),
P¼ 0.003] compared with those not reporting these symptoms
(Figure 2). No difference in adherence was observed for those
reporting gynecological symptoms in the placebo arm
[HR¼ 0.91 (0.69–1.20), P¼ 0.5]. For all other reported symp-
toms at 6 months, no significant differences between treatment
arms were observed with regard to adherence (Figure 2). The
majority of symptoms reported at 6 months among both treat-
ment groups were of mild or moderate severity. Non-adherence
was similar between those not reporting a symptom and those
reporting mild symptoms at 6 months (supplementary Figure S2,
available at Annals of Oncology online). We observed significant
trends for non-adherence with increasing severity for all reported
symptoms (P< 0.001), except for eye diseases (P¼ 0.8) and
osteoporosis (P¼ 0.9) (supplementary Figure S2, available at
Annals of Oncology online).
IBIS-II DCIS study
Postmenopausal women (n¼ 2980) diagnosed with DCIS within
6 months before randomization were allocated to receive 1 mg/
day anastrozole versus 20 mg/day tamoxifen. Women were
excluded from the current analysis if they did not start the allo-
cated medication (n¼ 32) or if they were ineligible (n¼ 18). This
left 2930 women (98.3%) for the adherence analysis (1486 tamox-
ifen versus 1444 anastrozole) (supplementary Figure S1, available
at Annals of Oncology online). For the analysis of the association
of early reported symptoms and adherence an additional 159
women who did not reach the 6 month follow-up point were
excluded (Figure 1). Baseline demographics were balanced
between treatment groups (supplementary Table S1, available at
Annals of Oncology online).
Overall, non-adherence was 33.3% and non-significantly dif-
ferent between anastrozole and tamoxifen [HR¼ 1.06 (0.94–
1.20), P¼ 0.4] (Figure 1). Mean time on study was also similar
between treatment arms (anastrozole: 3.99 years versus tamoxi-
fen: 3.95 years). As with the prevention study, rates of non-
adherence were greatest within the first 12–18 months and
decrease thereafter (Figure 1). In the univariate analysis, previous
HRT use [OR¼ 0.79 (0.67–0.92), P¼ 0.003], hysterectomy
[OR¼ 0.83 (0.70–0.98), P¼ 0.03], and oophorectomy
[OR¼ 0.75 (0.58–0.97), P¼ 0.03] were significantly associated
with decreased likelihood of adherence. Women who had a natu-
ral menopause [OR¼ 1.25 (1.04–1.50), P¼ 0.02] were signifi-
cantly more likely to be adherent than their counterparts
(supplementary Table S1, available at Annals of Oncology online).
In the multivariate analysis, only previous HRT use remained a
significant predictor of non-adherence [OR¼ 0.81 (0.69–0.95),
P¼ 0.009] in women with DCIS.
A total of 2770 women were included to investigate early
reported symptoms and adherence. At 6 months, significantly
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Figure 1. Kaplan–Meier plots for non-adherence and annual non-adherence rates (%) according to treatment arm for the IBIS-II prevention
(A, B) and DCIS (C, D) studies. Kaplan–Meier curves were calculated and tested for equality using log-rank test. All statistical tests were two-
sided. IBIS, International Breast cancer Intervention Study; HR, hazard ratio; CI, conﬁdence interval.
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more women randomized to anastrozole reported arthralgia
compared with tamoxifen (30.4% versus 20.3%, P< 0.001). In
contrast, significantly more women randomized to tamoxifen
reported hot flashes/night sweats (40.6% versus 46.7%,
P¼ 0.001) and gynecological symptoms (7.0% versus 12.8%,
P< 0.001). Women reporting hot flashes were significantly more
adherent than those not reporting these symptoms [HR¼ 1.18
(1.02–1.36), P¼ 0.02] (Table 1). Those on anastrozole reporting
these symptoms were significantly more adherent than their
counterparts [HR¼ 1.23 (1.00–1.52), P¼ 0.05], and a non-
significant increase in non-adherence was also observed for those
on tamoxifen (Figure 2). For all other symptoms, no association
with adherence was observed either overall or by treatment arm
(Table 1 and Figure 2). Non-adherence was similar between those
not reporting a symptom and those reporting mild symptoms at
6 months (supplementary Figure S2, available at Annals of
Table 1. Early reported symptoms at 6 months associated with non-adherence in the IBIS-II prevention and DCIS study
IBIS-II prevention IBIS-II DCIS
Non-adherence (%) HR (95% CI)a P-value Non-adherence (%) HR (95% CI)b P-value
Arthralgia
No (n¼2577) 30.0 – – No (n¼2069) 28.9 – –
Yes (n¼1027) 24.6 0.85 (0.75–0.97) 0.01 Yes (n¼702) 31.2 0.90 (0.77–1.05) 0.2
Hot ﬂashes/night sweats
No (n¼2224) 30.8 – – No (n¼1561) 31.3 – –
Yes (n¼1380) 32.0 1.02 (0.90–1.15) 0.8 Yes (n¼1210) 27.3 1.18 (1.02–1.36) 0.02
Gynecological
No (n¼3238) 30.6 – – No (n¼2496) 29.4 – –
Yes (n¼366) 37.4 0.78 (0.65–0.94) 0.008 Yes (n¼275) 30.9 0.93 (0.74–1.16) 0.5
Eye disease
No (n¼3424) 31.1 – – No (n¼2657) 29.4 – –
Yes (n¼180) 34.4 0.90 (0.69–1.16) 0.4 Yes (n¼114) 32.5 0.87 (0.63–1.22) 0.4
Osteoporosis
No (n¼3534) 31.3 – – No (n¼2717) 29.5 – –
Yes (n¼70) 30.0 1.00 (0.65–1.55) 0.9 Yes (n¼54) 31.5 0.92 (0.57–1.48) 0.7
aHR adjusted for age, hysterectomy, and previous IBIS-1 participation.
bHR adjusted for HRT.
IBIS, International Breast cancer Intervention Study; HR, hazard ratio; CI, conﬁdence intervals.
0.81 (0.67-0.97)
0.90 (0.75-1.07)
0.98 (0.82-1.16)
1.07 (0.90-1.26)
0.91 (0.69-1.20)
0.69 (0.55-0.88)
0.83 (0.58-1.18)
0.98 (0.67-1.42)
1.13 (0.58-2.18)
0.92 (0.52-1.63)
Hazard ratio (95% CI)*
0 1 2
0.88 (0.70-1.11)
0.90 (0.73-1.12)
1.14 (0.93-1.39)
1.23 (1.00-1.52)
0.90 (0.68-1.20)
0.99 (0.67-1.46)
0.90 (0.56-1.44)
0.86 (0.54-1.36)
0.74 (0.37-1.48)
1.08 (0.56-2.08)
Hazard ratio (95% CI)**
0 1 2
Arthralgia
Hot flashes
Gynecological
Eye Disease
Osteoporosis
Number of women
with symptom
Symptom
564
618
762
163
203
91
89
34
36
463 Arthralgia
Hot flashes
Gynecological
Eye Disease
Osteoporosis
Number of women
with symptom
Symptom
418
653
557
179
96
56
58
21
33
284
More adherentLess adherent
Placebo
Anastrozole
More adherentLess adherent
Tamoxifen
Anastrozole
*HR adjusted for age, hysterectomy, and previous IBIS-I participation; **HR adjusted for HRT. HRT=Hormone Replacement Therapy.
Figure 2. Forest plots for non-adherence (hazard ratios) among women reporting symptoms at 6months by treatment arm for the IBIS-II
prevention (A) and DCIS (B) studies. The squares represent the point estimates. Sizes of the squares represent the number of events. The hori-
zontal error bars show the 95% conﬁdence intervals (CI) of each hazard ratio. IBIS, International Breast cancer Intervention Study; CI, conﬁ-
dence interval.
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Oncology online). We observed significant trends for non-
adherence with increasing severity for arthralgia (P< 0.001), hot
flashes (P¼ 0.009), and gynecological symptoms (P¼ 0.03).
There were no significant trends for any other symptoms (supple
mentary Figure S2, available at Annals of Oncology online).
Discussion
In the IBIS-II prevention and DCIS trials, over one-third of
women were non-adherent for the full course of therapy. There
were no overall significant differences in study drop-outs by
treatment arm for either study. Arthralgia and gynecological
symptoms at any severity significantly reduced the likelihood of
adherence in the placebo and anastrozole groups of the preven-
tion trial, respectively. In the DCIS trial, hot flashes were associ-
ated with a higher likelihood of adherence. Associations between
symptoms and non-adherence strengthened with increasing
severity. Participant-reported early symptoms may be partially
responsible for non-adherence to anastrozole preventive therapy,
however, other factors are likely to play an important role.
Similarities in non-adherence between the treatment groups
suggest that some factors associated with non-adherence are
likely to be unrelated to anastrozole. Similar non-adherence rates
between treatment arms were also reported in the MAP.3 preven-
tion trial (32.8% exemestane versus 28.7% placebo) [19] and the
NSABP-B35 trial (35.6% anastrozole versus 35.8% tamoxifen)
[8]. Identifying strategies to reduce the burden of moderate and
severe symptoms could be one approach increase medication
adherence. However, identifying modifiable factors other than
medication induced side-effects that explain non-adherence
could improve behavioral interventions. Our previous systematic
review of uptake and adherence to breast cancer chemopreven-
tion suggests women’s perceived risk of breast cancer is likely to
play a role [10].
Non-adherence in the IBIS-I tamoxifen prevention trial
showed higher levels of study drop-outs in the first 12–18 months
of therapy [13] and a finding has been reported in the adjuvant
setting [20, 21]. We observed the same pattern in both the IBIS-II
prevention and DCIS trials. This consistency highlights that this
time period may be the most appropriate point to deliver inter-
ventions supporting adherence. Identifying the optimal timing of
interventions is important, but there is a paucity of strategies
shown to effectively improve adherence to endocrine therapy.
Identifying modifiable determinants of adherence to preventive
therapy should be prioritized, so they can be incorporated into
strategies to improve medication taking behavior.
Participant-reported symptoms do not completely explain
non-adherence to preventive therapy. Arthralgia, hot flashes/
night sweats, and gynecological symptoms were more common
among women taking anastrozole in the IBIS-II prevention trial.
Fewer women taking anastrozole in the IBIS-II DCIS trial
reported hot flashes/night sweats or gynecological symptoms,
however arthralgia was more common compared with the
tamoxifen treatment arm. The NSABP-B35 observed similar
trends [22], but demonstrated no significant differences in qual-
ity of life between women taking anastrozole and tamoxifen.
Strategies to manage these symptoms are required to ensure qual-
ity of life is not affected among women taking preventive therapy.
This study has strengths and limitations. We are among the first
to provide a detailed report of the relationship between symptoms
and non-adherence among women taking anastrozole for preventive
therapy. The data derive from two large international randomized
studies that were carefully monitored throughout. However, because
these data were from motivated participants willing to enroll in a
clinical trial, we may have over-estimated the proportion of women
who are able to complete the full course of therapy. In addition, we
were not able to investigate concurrent medication associated with
symptoms relieve, which may contribute to better adherence. There
is no gold standard measure of medication adherence, our reported
outcome was recorded during clinic visits and may be an inflated
estimate [23]. Quality of life assessments that encapsulate the full
impact of symptoms on everyday life may be more closely associated
with adherence [24]. We noted a weaker than expected relationships
between symptoms reported at 6 months and non-adherence. One
possibility is that late-onset symptoms could be responsible for sub-
sequent trial drop-out. However, this is unlikely to account for a
large amount of drop-outs as the majority of treatment induced
side-effects occur in the first year of therapy [25]. Our 6-month
assessment may also be identifying symptoms that are transient in
nature. Women experiencing symptoms that persist for longer or
become more severe may be more likely to drop-out, and this would
not be captured by our analysis.
In conclusion, non-adherence with anastrozole was moderate
in both the IBIS-II prevention and DCIS trials. Only women
reporting moderate or severe symptoms were less likely to be
adherent. Identifying factors other than medication induced
side-effects that explain non-adherence could help to target
future intervention strategies to support medication taking
behavior. Once interventions have been developed, they should
be targeted at women within the first 18 months of therapy, as
this is when medication cessation is most likely.
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